iNova Pharmaceuticals (PRIVATE.INOVA)

Overall impact
C (53)

Commentary

iNova Pharmaceuticals is an average overall performer. With a 'C' rating of 52.8 for overall impact (47th percentile compared to all companies), iNova Pharmaceuticals ranks 207th out of 243 industry peers, behind Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 203 others, and ahead of PPD Incorporated, Azurity Pharmaceuticals, Teva and 33 others. On top material causes for iNova Pharmaceuticals's industry (Pharmaceuticals), iNova Pharmaceuticals performs well in Reduced Waste (80.3 score), Reduced Waste (80.3) and Reduced Waste (80.3) and performs poorly in Reduced Use of tobacco (39.7 score), Improved Mental Health (11.2), Fair Labor Practices (38.4) and 12 other causes where it received a 'D' or 'F' score.
Screens
Fur
Impact
Cause PRIVATE.INOVA
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
500
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Singapore
Share classes
PRIVATE.INOVA
Description
Manufacturer of prescription and over-the-counter medicines intended to deliver products that will improve people's health and well-being every day. The company offers therapeutic medicines for areas including weight management, cough, cold and flu, pain management, health supplements, dermatology, sun care and female health products.
Material causes
Ethos considers the following causes material for iNova Pharmaceuticals, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.